EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Cost-effectiveness of atosiban versus placebo for threatened preterm birth (APOSTEL 8 trial)

Larissa van der Windt iD, Martijn Oudijk iD, Job Klumper iD, Tobias Nijman, Judith Bosmans, Ben Willem Mol, Joris van der Post iD, Carolien Roos, Stavros Petrou iD, Kate Walker

PLOS One · 05.11.2026 · 21 (11) · e0347475

DOI: 10.1371/journal.pone.0347475 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, online erschienen am 05.11.2026. Verfasst von Larissa van der Windt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands. Hauptthemen laut MEDLINE: Premature Birth, Vasotocin, Tocolytic Agents. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zonmw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To assess the cost-effectiveness of treatment with atosiban compared to placebo for threatened preterm birth from 30 +0 to 33 +6 weeks of gestation.

Methods

We performed an economic evaluation from a societal perspective alongside the multicentre randomised controlled APOSTEL 8 trial, including 755 participants with threatened preterm birth from 30 +0 to 33 +6 weeks of gestation who were randomised to atosiban or placebo, of whom 752 (884 infants) were included in the intention-to-treat analysis. Costs, collected between randomisation and three months corrected child age, were measured using a combination of hospital records and the self-reported iMTA Medical and Productivity Cost Questionnaires and estimated at infant level. The main outcome measure was cost-effectiveness expressed in terms of incremental cost per severe adverse neonatal outcome prevented. Multiple imputation by chained equations was used to handle missing data. Non-parametric bootstrapping was used to estimate statistical uncertainty surrounding incremental cost-effectiveness outcomes.

Findings

The difference in mean costs between the atosiban group (€40,743.1) and the placebo group (€40,793.6) was not statistically significant (mean difference: -€50.5; 95% confidence interval (CI) −4037.6 to 3936.7). The incremental cost per severe adverse neonatal outcome prevented was dominant (-€5286.6), falling in the south-east quadrant of the cost-effectiveness plane, indicating cost-savings and reduced severe adverse neonatal outcomes by atosiban. However, the bootstrapped cost-effect pairs were distributed across all four quadrants of the cost-effectiveness plane, indicating high uncertainty surrounding cost-effectiveness estimates. The probability of cost-effectiveness of atosiban reached 50% at a willingness to pay threshold of €33,023.3 per severe adverse neonatal outcome prevented.

Interpretation

This economic evaluation did not demonstrate that atosiban is a cost-effective treatment for threatened PTB from 30 +0 to 33 +6 weeks gestation. In addition to the absence of clinical benefit, our findings show no economic advantage, further discouraging its routine use at this gestational age. These results contribute to optimizing evidence-based management of threatened preterm birth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Premature BirthVasotocinTocolytic AgentsHumansCost-Benefit AnalysisFemaleCost-Effectiveness AnalysisPregnancyInfant, Newborn

Substanzen

atosibanVasotocinTocolytic Agents

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands.
  • Amsterdam Reproduction and Development Research Institute, Amsterdam, Netherlands.
  • Department of Obstetrics and Gynaecology, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Department of Obstetrics and Gynaecology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
  • Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, Netherlands.
  • Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia.

ORCID-Profile: Larissa van der Windt, Martijn Oudijk, Job Klumper, Joris van der Post, Stavros Petrou

Förderung

  • Zonmw

Zitieren

APA

van der Windt, L., Oudijk, M., Klumper, J., Nijman, T., Bosmans, J., Mol, B. W., van der Post, J., Roos, C., Petrou, S., & Walker, K. (2026). Cost-effectiveness of atosiban versus placebo for threatened preterm birth (APOSTEL 8 trial). PLOS One, 21(11), e0347475. https://doi.org/10.1371/journal.pone.0347475

Vancouver

van der Windt L, Oudijk M, Klumper J, Nijman T, Bosmans J, Mol BW, et al. Cost-effectiveness of atosiban versus placebo for threatened preterm birth (APOSTEL 8 trial). PLOS One. 2026;21(11):e0347475. doi:10.1371/journal.pone.0347475

BibTeX
@article{vanderWindt2026,
  author = {van der Windt, Larissa and Oudijk, Martijn and Klumper, Job and Nijman, Tobias and Bosmans, Judith and Mol, Ben Willem and van der Post, Joris and Roos, Carolien and Petrou, Stavros and Walker, Kate},
  title = {Cost-effectiveness of atosiban versus placebo for threatened preterm birth (APOSTEL 8 trial)},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {e0347475},
  doi = {10.1371/journal.pone.0347475}
}
Kostenlos starten →